{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:53:57Z","timestamp":1792428837780,"version":"4.5.0"},"reference-count":74,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T00:00:00Z","timestamp":1546819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Advanced age is one of the major determinants of frailty in patients with cancer-associated thrombosis. However, multiple other factors contribute to frailty in these patients. The identification of frailty in patients with cancer-associated thrombosis is critical as it influences the complexity of the anticoagulant treatment in this population at high risk of venous thromboembolism and bleeding. Factors that contribute to frailty in patients with cancer-associated thrombosis include age, type of cancer, comorbidities such as chronic kidney disease, poly-pharmacotherapy, treatment compliance, cognitive impairment, anemia, thrombocytopenia, mobility, nutritional status, Eastern Cooperative Oncology Group grade, risk of falls, and reduced life expectancy. In the absence of specific clinical studies current anticoagulant treatment guidelines for the management are not fully applicable to frail patients with cancer. The anticoagulant treatment should therefore benefit from a tailored approach based on an algorithm that takes into account the specificities of the malignant disease.<\/jats:p>","DOI":"10.3390\/cancers11010048","type":"journal-article","created":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T03:22:31Z","timestamp":1547090551000},"page":"48","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Treatment and Prevention of Cancer-Associated Thrombosis in Frail Patients: Tailored Management"],"prefix":"10.3390","volume":"11","author":[{"given":"Florian","family":"Scott\u00e9","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Supportive Care. H\u00f4pital Foch, 92150 Suresnes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Leroy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Supportive Care. H\u00f4pital Foch, 92150 Suresnes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Chastenet","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Supportive Care. H\u00f4pital Foch, 92150 Suresnes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Aumont","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Supportive Care. H\u00f4pital Foch, 92150 Suresnes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidal","family":"Benatar","sequence":"additional","affiliation":[{"name":"Heathics Clinical Consultants. 111 rue des Tennerolles, 92210 Saint-Cloud, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isma\u00efl","family":"Elalamy","sequence":"additional","affiliation":[{"name":"Department of Hematology, H\u00f4pital Tenon, H\u00f4pitaux Universitaires de l\u2019Est Parisien, Sorbonne Universit\u00e9, INSERM UMR S938, 75012 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,1,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in elderly people","volume":"381","author":"Clegg","year":"2013","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/gerona\/glv133","article-title":"Frailty in Older Adults: A Nationally Representative Profile in the United States","volume":"70","author":"Seplaki","year":"2015","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: Evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_4","first-page":"302","article-title":"Anticoagulants in frail patients. Seven situations at risk","volume":"43","author":"Elalamy","year":"2018","journal-title":"J. Med. Vasc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3747\/co.21.1864","article-title":"Cancer and venous thromboembolic disease: From molecular mechanisms to clinical management","volume":"21","author":"Donnellan","year":"2014","journal-title":"Curr. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/jth.14139","article-title":"Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer","volume":"16","author":"Parker","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/CIRCULATIONAHA.111.051920","article-title":"Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism","volume":"126","author":"Louzada","year":"2012","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1055\/s-0037-1604086","article-title":"The Modified Ottawa Score and Clinical Events in Hospitalized Patients with Cancer-Associated Thrombosis from the Swiss VTE Registry","volume":"43","author":"Alatri","year":"2017","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1160\/TH17-02-0116","article-title":"Low discriminating power of the modified Ottawa VTE risk score in a cohort of patients with cancer from the RIETE registry","volume":"117","author":"Alatri","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/CIRCULATIONAHA.110.007864","article-title":"Bleeding risk in very old patients on vitamin K antagonist treatment: Results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation","volume":"124","author":"Poli","year":"2011","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1517\/14740338.2015.1052739","article-title":"Safety of anticoagulant treatment in cancer patients","volume":"14","author":"Wilts","year":"2015","journal-title":"Expert Opin. Drug. Saf."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Akl, E.A., Kahale, L., Barba, M., Neumann, I., Labedi, N., Terrenato, I., Sperati, F., Muti, P., and Sch\u00fcnemann, H. (2014). Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst. Rev., CD006650.","DOI":"10.1002\/14651858.CD006650.pub4"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0049-3848(10)70015-3","article-title":"Bleeding complications associated with anticoagulant therapy in patients with cancer","volume":"125","author":"Nieto","year":"2010","journal-title":"Thromb. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1160\/TH08-06-0390","article-title":"Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry","volume":"100","author":"Nieto","year":"2008","journal-title":"Thromb. Haemost."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients with Active Cancer: A Randomized Clinical Trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/jth.12605","article-title":"Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism","volume":"12","author":"Kooiman","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an Oral Factor Xa Inhibitor with Low Molecular Weight Heparin in Patients with Cancer with Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_22","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"Kuter","year":"2015","journal-title":"Oncology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/jth.14007","article-title":"Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study","volume":"16","author":"Kamphuisen","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1111\/jth.14253","article-title":"The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism","volume":"16","author":"Palareti","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/jth.12239","article-title":"The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: Results of the prospective collaborative EPICA study","volume":"11","author":"Poli","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/j.1532-5415.2012.04054.x","article-title":"Prevalence of frailty in community-dwelling older persons: A systematic review","volume":"60","author":"Collard","year":"2012","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11239-015-1313-4","article-title":"Guidance for the prevention and treatment of cancer-associated venous thromboembolism","volume":"41","author":"Khorana","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1634\/theoncologist.2013-0239","article-title":"New oral anticoagulants and the cancer patient","volume":"19","author":"Short","year":"2014","journal-title":"Oncologist"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2352-3026(14)70018-3","article-title":"Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): A pooled subgroup analysis of two randomised controlled trials","volume":"1","author":"Prins","year":"2014","journal-title":"Lancet Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1634\/theoncologist.2013-0226","article-title":"Venous thromboembolism risk in patients with cancer receiving chemotherapy: A real-world analysis","volume":"18","author":"Lyman","year":"2013","journal-title":"Oncologist"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update 2014","volume":"33","author":"Lyman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/S1470-2045(16)30369-2","article-title":"International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"17","author":"Farge","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2014.07.017","article-title":"Retrospective evaluation of thromboembolic events in patients with non-small cell lung cancer treated with platinum-based chemotherapy","volume":"86","author":"Mellema","year":"2014","journal-title":"Lung Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.lungcan.2012.09.007","article-title":"Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer","volume":"78","author":"Connolly","year":"2012","journal-title":"Lung Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.6004\/jnccn.2013.0164","article-title":"Venous Thromboembolism Prevention in Cancer Outpatients","volume":"11","author":"Khorana","year":"2013","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: The Protecht score","volume":"7","author":"Verso","year":"2012","journal-title":"Intern. Emerg. Med."},{"key":"ref_40","first-page":"2084","article-title":"Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?","volume":"138","author":"Pelzer","year":"2013","journal-title":"Dtsch. Med. Wochenschr."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/jth.13378","article-title":"Predictors of active cancer thromboembolic outcomes: Validation of the Khorana score among patients with lung cancer","volume":"14","author":"Mansfield","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","article-title":"A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study","volume":"22","author":"Gerotziafas","year":"2017","journal-title":"Oncologist"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bindu Kanapuru, H.S., Myers, A., Beaver, J., Kwitkowski, V.E., Farrell, A.T., and Pazdur, R. (2017). Enrollment of Older Adults in Clinical Trials Evaluating Patients with Hematologic Malignancies\u2014The Food and Drug Administration (FDA) Experience, American Society of Hematology (ASH).","DOI":"10.1182\/blood.V130.Suppl_1.861.861"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1055\/s-0031-1273085","article-title":"Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis","volume":"37","author":"Zamagni","year":"2011","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/cncr.20405","article-title":"Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease","volume":"101","author":"Srkalovic","year":"2004","journal-title":"Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","article-title":"Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy","volume":"98","author":"Zangari","year":"2001","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1002\/cncr.24490","article-title":"A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy","volume":"115","author":"Tucci","year":"2009","journal-title":"Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/cncr.31551","article-title":"Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics","volume":"124","author":"Cronin","year":"2018","journal-title":"Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.ackd.2017.05.006","article-title":"Kidney Toxicities Associated with Novel Cancer Therapies","volume":"24","author":"Lefebvre","year":"2017","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1681\/ASN.2004100843","article-title":"Renal failure associated with cancer and its treatment: An update","volume":"16","author":"Humphreys","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e000091","DOI":"10.1136\/esmoopen-2016-000091","article-title":"Renal insufficiency and cancer treatments","volume":"1","author":"Janus","year":"2016","journal-title":"ESMO Open"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.3324\/haematol.13055","article-title":"Recurrent thromboembolism and major bleeding during oral anticoagulant therapy in patients with solid cancer: Findings from the RIETE registry","volume":"93","author":"Prandoni","year":"2008","journal-title":"Haematologica"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.amjmed.2006.04.028","article-title":"Venous thromboembolism in patients with renal insufficiency: Findings from the RIETE Registry","volume":"119","author":"Monreal","year":"2006","journal-title":"Am. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1111\/jth.12411","article-title":"Impact of chronic kidney disease on the risk of clinical outcomes in patients with cancer-associated venous thromboembolism during anticoagulant treatment","volume":"11","author":"Kooiman","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1055\/s-0038-1641150","article-title":"Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study","volume":"118","author":"Bauersachs","year":"2018","journal-title":"Thromb. Haemost."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.critrevonc.2018.06.015","article-title":"Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences","volume":"129","author":"Bellesoeur","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_59","first-page":"i2868","article-title":"Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: Post hoc analysis of the ARISTOTLE trial","volume":"353","author":"Brouwer","year":"2016","journal-title":"BMJ"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1161\/CIRCOUTCOMES.109.884171","article-title":"Cognitive function and anticoagulation control in patients with atrial fibrillation","volume":"3","author":"Flaker","year":"2010","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.thromres.2016.05.020","article-title":"Intracranial subdural hematomas with elevated rivaroxaban concentration and subsequently detected spinal subdural hematoma: A case report","volume":"143","author":"Yamaguchi","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V122.21.2310.2310","article-title":"Treatment of cancer-associated thrombosis","volume":"122","author":"Lee","year":"2013","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"023001","DOI":"10.1088\/2057-1739\/aa6c05","article-title":"Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer","volume":"3","author":"Sylman","year":"2017","journal-title":"Converg. Sci. Phys. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s11239-018-1610-9","article-title":"Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism","volume":"45","author":"Kuperman","year":"2018","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.thromres.2016.11.017","article-title":"Aplastic anemia and risk of deep vein thrombosis and pulmonary embolism: A nationwide cohort study","volume":"149","author":"Lin","year":"2017","journal-title":"Thromb. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.4022\/jafib.1870","article-title":"What is the Impact of Frailty on Prescription of Anticoagulation in Elderly Patients with Atrial Fibrillation? A Systematic Review and Meta-Analysis","volume":"10","author":"Oqab","year":"2018","journal-title":"J. Atr. Fibrillation"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jamda.2014.12.008","article-title":"Thromboembolic prevention in frail elderly patients with atrial fibrillation: A practical algorithm","volume":"16","author":"Granziera","year":"2015","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Lee, A.Y., Bauersachs, R., Janas, M.S., Jarner, M.F., Kamphuisen, P.W., Meyer, G., Khorana, A.A., and CATCH Investigators (2013). CATCH: A randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-284"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer","volume":"119","author":"Hull","year":"2006","journal-title":"Am. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1076029606293692","article-title":"Secondary prevention of venous thromboembolic events in patients with active cancer: Enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period","volume":"12","author":"Deitcher","year":"2006","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Carrier, M., Abou-Nassar, K., Mallick, R., Tagalakis, V., Shivakumar, S., Schattner, A., Kuruvilla, P., Hill, D., Spadafora, S., and Marquis, K. (2018). Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa1814468"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1055\/s-0038-1667001","article-title":"Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study","volume":"118","author":"Kraaijpoel","year":"2018","journal-title":"Thromb. Haemost."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/1\/48\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:23:57Z","timestamp":1760185437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/1\/48"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,7]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1]]}},"alternative-id":["cancers11010048"],"URL":"https:\/\/doi.org\/10.3390\/cancers11010048","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,7]]}}}